The agreement does not include Japan, which is yet to be partnered.
In exchange for development and commercialization rights, AstraZeneca has agreed to pay Cubist $10.25 million cash upfront. In addition, Cubist will receive payments on reaching regulatory and sales milestones. AstraZeneca will pay Cubist an undisclosed price for the supply of Cubicin vials to be sold in the licensed territory.
“China is a very important growth market for pharmaceuticals, in particular antibiotics such as Cubicin,” said Mike Bonney, president and CEO of Cubist.
Cubicin is currently the only once-daily bactericidal antibiotic approved in the US indicated for the treatment of complicated skin and skin structure infections. Cubicin is also approved in the US as therapy for blood stream infections.